| Literature DB >> 31617086 |
Maria A van Agthoven1, David P A Kilgour1,2, Alice M Lynch1,3, Mark P Barrow1, Tomos E Morgan1, Christopher A Wootton1, Lionel Chiron4, Marc-André Delsuc4,5, Peter B O'Connor6.
Abstract
Two-dimensional mass spectrometry (2D MS) is a data-independent tandem mass spectrometry technique in which precursor and fragment ion species can be correlated without the need for prior ion isolation. The behavior of phase in 2D Fourier transform mass spectrometry is investigated with respect to the calculation of phase-corrected absorption-mode 2D mass spectra. 2D MS datasets have a phase that is defined differently in each dimension. In both dimensions, the phase behavior of precursor and fragment ions is found to be different. The dependence of the phase for both precursor and fragment ion signals on various parameters (e.g., modulation frequency, shape of the fragmentation zone) is discussed. Experimental data confirms the theoretical calculations of the phase in each dimension. Understanding the phase relationships in a 2D mass spectrum is beneficial to the development of possible algorithms for phase correction, which may improve both the signal-to-noise ratio and the resolving power of peaks in 2D mass spectra.Entities:
Keywords: Data processing; Fourier transform; Mass spectrometry; Phase correction; Two-dimensional mass spectrometry
Year: 2019 PMID: 31617086 PMCID: PMC6914722 DOI: 10.1007/s13361-019-02308-1
Source DB: PubMed Journal: J Am Soc Mass Spectrom ISSN: 1044-0305 Impact factor: 3.109
Scheme 1(a) Experimental script of Gäumann’s pulse sequence for 2D FT-ICR MS. (b) Experimental script of pulse sequence to map fragmentation zones and to optimize the parameters for the 2D MS pulse sequence
Figure 1ECD tandem mass spectrum for substance P (MH33+ and MH22+ precursor ions) using the pulse sequence in Scheme 1a with a t1 delay of 1.0 μs (a) in magnitude mode (b) in absorption mode. The insets on the left are zoom-ins of the spectra between m/z 200–650 and the insets on the right are zoom-ins of the spectra between m/z 680–1400
Figure 2Absorption mode ECD tandem mass spectra for substance P using the pulse sequence in Scheme 1a with a t1 delay of 1.0–5.0 μs (t1 delay of 1.0 is from the same spectrum as shown in Figure 1b). The column in the middle shows the peak assigned to the MH22+ precursor. The columns on the left and right show the peak for the c5 and c7 fragments for different values of t1 respectively
Figure 3Magnitude mode IRMPD tandem mass spectra for angiotensin 1 using the pulse sequence in Scheme 1b with an amplitude of (a) 1 Vpp and (b) 31 Vpp for the first pulse of the pulse sequence
Figure 4Left side: Ion intensity vs. RF excitation voltage for the pulse sequence in Scheme 1b for (a) MH33+ of angiotensin, (b) the b92+ fragment, and (c) the IH+ internal fragment. Right side: Ion intensity vs. encoding delay t1 for the pulse sequence in Scheme 1a for (d) MH33+ of angiotensin, (e) the b92+ fragment, and (f) the IH+ internal fragment
Figure 5Normalized ion intensity vs. encoding delay t1 for the pulse sequence in Scheme 1a for (a) the 12C, 1×13C, and 2×13C isotopes of MH33+ of angiotensin 1, (b) the 12C and 1×13C isotopes of the (HPF-H2O)+ fragment at m/z 364.1768, (c) the 12C and 1×13C isotopes of the y93+ fragment at m/z 394.5575, and (d) the 12C and 1×13C isotopes of the b92+ fragment at m/z 583.2987